Today: 3 July 2026
Browse Category

EPA:ABVX 16 December 2025 - 30 June 2026

Abivax stock jumps as safety denominator eases obefazimod cancer worry

Abivax stock jumps as safety denominator eases obefazimod cancer worry

Abivax SA rose sharply in Paris on Tuesday after late Monday data gave investors a cleaner way to judge cancer risk in its ulcerative colitis drug programme. Euronext Paris was open for a regular session, with June 30 listed as a 0900-1730 CEST trading day. The stock was last shown at 113.10 euros, up 35.77%, with a five-day gain of 32.05% and a year-to-date loss cut to 6.06%, MarketScreener data showed. U.S.-listed shares had jumped 26.4% in extended trading after the release, Reuters reported.
30 June 2026
···
Abivax (NASDAQ:ABVX) ADS gain $2.3B after obefazimod safety news; Paris session yet to start

Abivax (NASDAQ:ABVX) ADS gain $2.3B after obefazimod safety news; Paris session yet to start

Abivax S.A. is set for a lagged Paris opening after its U.S. ADS jumped in after-hours trading. Investors reacted to new clinical data on obefazimod, Abivax’s ulcerative colitis drug. The latest news hits late, but the drop earlier this month wasn’t about whether the drug works. It was about the potential cancer risk and what that could mean for the drug’s label. Abivax put out the release at 22:05 CEST, after Euronext Paris had already closed for the day at 17:30 and just past the U.S. market close. Euronext Paris trades from 9:00 a.m. to 5:30 p.m. local time and, according to its 2026 holiday calendar, June 30 isn’t a holiday.
30 June 2026
···
Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax shares dropped hard Tuesday, despite positive late-stage trial results for its obefazimod drug. Investors focused on reported cancer and dysplasia cases in patients on the higher dose. The stock traded at 63.10 euros on Euronext Paris, well below Monday’s closing price of 111.80 euros, after touching 62.80 euros earlier. Over in the U.S., its Nasdaq ADRs were last at $72.86, down some 44% late in the session. Abivax had turned into one of Europe’s biggest biotech bets, as most of its price depended on obefazimod’s prospects as an oral ulcerative colitis drug. Reuters said its shares led the drop on Europe’s STOXX 600 in Paris this morning. The stock had surged over 16 times last year.
2 June 2026
····
Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax shares tumbled in late U.S. trading on Monday, despite the French biotech putting out positive late-stage results for its main ulcerative colitis drug. The American depositary shares were at $86.01 after hours, a drop of 33.7% from their regular close at $129.69, according to Google Finance. Abivax cleared a key clinical hurdle with the results, setting up for a planned U.S. submission. Phase 3 is the last big step in trials before regulators rule on drug approval, usually the final check before sales can begin.
2 June 2026
···
ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

PARIS / NEW YORK — December 22, 2025 — ABIVAX Société Anonyme stock is back in the spotlight on Monday after renewed takeover chatter tied to U.S. pharma giant Eli Lilly—arriving the same morning Abivax’s addition to the Nasdaq Biotechnology Index becomes effective. The combination is fueling a sharp move in ABVX shares and re-igniting debate about whether 2025’s biotech breakout is now morphing into an M&A story. Abivax shares rose sharply in Monday trading as media reports revived speculation that Eli Lilly could be exploring a deal for the French biotech. Reuters’ market update cited Abivax jumping 7.6% on the day amid takeover chatter. Reuters
22 December 2025
··
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

December 22, 2025 — ABIVAX Société Anonyme is back in the spotlight today, with traders juggling two storylines that can move a biotech stock fast: renewed takeover speculation involving Eli Lilly and Abivax’s addition to the Nasdaq Biotechnology Index, effective before today’s market open. GlobeNewswire+2Investing.com+2 In early market action, multiple outlets reported double‑digit gains in Abivax’s U.S. premarket trading and strong moves in Paris, making ABVX one of the morning’s most-watched biotech tickers. Benzinga+2Investing.com+2
22 December 2025
····
ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

December 16, 2025 — ABIVAX Société Anonyme is back in the spotlight today after publishing third-quarter 2025 financial results and reiterating a long cash runway—news that didn’t stop the stock from pulling back as investors digested widening losses and the sheer scale of the rally already priced in. In U.S. trading, Abivax’s Nasdaq-listed shares were down about 5% around mid-session, at roughly $111–$112. StockAnalysis In Paris, Abivax shares were also lower earlier in the day, with one market report citing a drop of about 5.7% during the European morning. Investing.com South Africa
16 December 2025
···

Stock Market Today

  • UiPath (NYSE:PATH) Rallies 11% as Short Interest Climbs and Buyback Kicks In Before Short Seller Report
    July 3, 2026, 10:02 AM EDT. UiPath shares jumped 11.2% to $11.71, pushing past major tech ETFs, with no new operations news out. The move showed up as short interest reached 32.23% of float, raising questions about a possible squeeze. Trading was heavy-volume hit 58.4 million shares on July 2, 153% over the 65-day average. The company's buyback remains a factor: $243.8 million was repurchased in Q1 and a fresh $500 million plan is underway. UiPath now sees Q2 net ARR growth of $28-$33 million, lower than $49 million in the prior quarter. As of April 30, cash and equivalents totaled $1.42 billion, about 23% of market cap. All eyes now on the July 10 short seller report as guidance and positioning could swing the price further.
Go toTop